Table 1.
Clinical characteristics of patients.
| Patient | 1 | 2 | 3 | 4 |
|---|---|---|---|---|
| Age (years) | 30 | 38 | 41 | 57 |
| Sex | Female | Female | Female | Female |
| MS type | RRSM | RRSM | RRSM | RRSM |
| Duration of MS disease (years) | 1 | 1 | 14 | 6 |
| EDSS | 4.0 | 3.5 | 4.5 | 4.5 |
| Applied DMT | Dimethyl fumarate | Dimethyl fumarate | Interferon β1b | Glatiramer acetate |
| Lymphocyte count [103/μl] (N: 1−3.3) | 0.86 | 1.1 | 2.5 | 2.75 |
| Comorbidities | Hypothyroidism, lower limb varicose veins, overweight (BMI 29.06) | None | Hashimoto's thyroiditis | Dyslipidaemia, migraine headaches |
| PCR-confirmed COVID-19 infection | Yes | Yes | Yes | Yes |
| Symptoms and duration of COVID-19 | Osteoarticular pains, fever up to 38 °C, diarrhoea, general weakness, headaches, paraesthesias of the left upper limb, 7 days |
Headaches and dizziness, rhinitis, fever up to 38 °C, olfactory and taste disorders, attention deficit disorder, 10 days |
Osteoarticular pains, fever up to 38 °C, headaches, olfactory and taste disorders, 6 days |
Osteoarticular pains, headaches and dizziness, coughing, fever > 38 °C 12 days |
| DMT treatment during COVID-19 infection | Yes | No | Yes | No |
MS – multiple sclerosis; RRSM – relapsing-remitting MS; EDSS – Expanded Disability Status Scale; DMT – disease modifying therapies; PCR – polymerase chain reaction; COVID-19 –Coronavirus Disease 2019.